Details for New Drug Application (NDA): 216951
✉ Email this page to a colleague
The generic ingredient in JESDUVROQ is daprodustat. One supplier is listed for this compound. Additional details are available on the daprodustat profile page.
Summary for 216951
Tradename: | JESDUVROQ |
Applicant: | Glaxosmithkline |
Ingredient: | daprodustat |
Patents: | 6 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 216951
Generic Entry Date for 216951*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 216951
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
JESDUVROQ | daprodustat | TABLET;ORAL | 216951 | NDA | GlaxoSmithKline LLC | 0173-0897 | 0173-0897-13 | 30 TABLET, FILM COATED in 1 BOTTLE (0173-0897-13) |
JESDUVROQ | daprodustat | TABLET;ORAL | 216951 | NDA | GlaxoSmithKline LLC | 0173-0903 | 0173-0903-13 | 30 TABLET, FILM COATED in 1 BOTTLE (0173-0903-13) |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 1MG | ||||
Approval Date: | Feb 1, 2023 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Feb 1, 2028 | ||||||||
Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Patent: | ⤷ Subscribe | Patent Expiration: | Mar 13, 2038 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patented Use: | A METHOD OF TREATING ANEMIA | ||||||||
Patent: | ⤷ Subscribe | Patent Expiration: | Jun 22, 2027 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
Patented Use: | A METHOD OF TREATING ANEMIA |
Complete Access Available with Subscription